We also observed reductions in expression of PD-L1 mRNA in several NSCLC cell lines with endogenous KRAS mutations following treatment with NAC, reduced glutathione, or MK2 inhibitor III (Figure S5D), although we noted some heterogeneity in response between the four cell lines tested. The gene discussed is MAPKAPK2; the disease is non-small cell lung carcinoma.